ClinicalTrials.gg
RecruitingNCT06301373Updated May 12, 2026

Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis

An interventional study of Methotrexate Combined With Tofacitinib and Methotrexate in Rheumatoid Arthritis, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 5 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Planned enrollment
57th of 113
130 · median 130
Started
2024
with 2 others
No phase
4 of 113
2 open now
Registered
108th of 113
by date

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 57th largest by planned enrollment, is one of 3 that started in 2024, is one of 4 with no phase, and was the 108th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Rheumatoid arthritis (RA) is the leading cause of disability in Chinese women. We established a synovial pathology queue in the early stage and proposed a new synovial immunopathology classification. We found that baseline myeloid stromal RA patients had severe conditions and poor outcome. Early identification of synovial myeloid stromal RA patients and intensified treatment are key to improving RA efficacy.

This project aims to conduct a randomized, controlled, open label, multicenter clinical study on early intensified treatment of RA based on synovial pathology classification. 130 adult patients with synovial myeloid stromal type of primary treatment moderate to severe active RA were planned to be enrolled in three centers: Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University, and Guangzhou Panyu Central Hospital. They were randomly divided into an intensive treatment group and a conventional treatment group in a 1:1 ratio. The intensive treatment group was treated with methotrexate combined with tofacitinib, while the conventional treatment group was treated with methotrexate monotherapy. The expected intervention period is 12 weeks, with a follow-up period of 48 weeks. The primary endpoint is the proportion of subjects who achieved ACR20 at week 12. Secondary endpoint indicators include improvement in disease activity and joint function among subjects at different follow-up points, safety, and the proportion of subjects who experienced joint destruction progression at week 48.

This project proposes the concept of achieving precise diagnosis of RA based on synovial pathology classification, and explores the efficacy of early methotrexate combined with tofacitinib intensified treatment for patients with synovial medullary stromal RA who have poor conventional treatment efficacy, providing high-level clinical evidence for achieving precise initial treatment of RA treatment guidelines.

Read the detailed description

Rheumatoid arthritis (RA) is the leading cause of disability in Chinese women, but it cannot be cured. About 25%-40% of RA patients experience bone erosion within 6 months after experiencing joint symptoms. The first year after the onset of RA is the best window of treatment opportunity, and the earlier standardized treatment is initiated, the more effective RA treatment will be. RA patients have strong heterogeneity and lack effective evaluation indicators for early identification of patients with poor prognosis. Therefore, currently, domestic and foreign RA treatment guidelines do not include adverse prognostic factors in the initial stage. All RA patients are recommended to start treatment with methotrexate (MTX) monotherapy. If the improvement is not good after 3 months or does not meet the standard after 6 months, csDMARDs or targeted drug biologics or JAK inhibitors should be combined. However, clinical studies have found that the effective rate of MTX monotherapy after 3 months is only 30% to 50%, and most patients require combination therapy.

The pathological basis of RA is synovitis. In the early stage, we established a synovial pathology cohort and proposed a new synovial immunopathology classification. We found that baseline medullary stromal type (58%) RA patients had severe conditions, poor efficacy, and a risk of joint destruction progression after 1 year of imaging was 3.2 times higher than other types (Front Immunol, 2021), Among them, the efficacy of combining traditional synthetic DMARDs or biological agents for 3 months in the treatment of newly treated synovial medullary stromal RA patients is not as good as other types of patients [the core criteria for RA disease activity assessment of the American Society of Rheumatology reached 20% improvement (ACR20): 52% vs. 75%]. Therefore, early identification of patients with synovial myeloid stromal RA and intensified treatment are key to improving the efficacy of RA.

The plan for intensified treatment of RA includes the combination of MTX and biological agents or JAK inhibitors, where biological agents only target specific immune cells or cytokines, are expensive, require intravenous medication, and are prone to producing anti drug antibodies. JAK inhibitors can target JAK related inflammatory pathways in different cells, are convenient to take orally, and do not produce anti drug antibodies. The JAK inhibitors that have been listed in China include tofacitinib, Barretinib, and Upatinib. Among them, tofacitinib has the longest use time, good efficacy and safety, and is affordable after national centralized procurement, with strong promotability.

The characteristic of medullary stromal synovium is multicellular activation, which can secrete inflammatory factors and a large amount of matrix metalloproteinases (MMPs). It has been reported that tofacitinib can inhibit the production of synovial MMP-3. Our preliminary retrospective analysis showed that in RA patients with poor efficacy of csDMARDs or biologics, MTX combined with tofacitinib was used for treatment for 3 months, resulting in a 56% ACR20 and a significant decrease in serum MMP-3. This suggests that MTX combined with tofacitinib can be used as an intensive treatment for synovial myeloid stromal RA patients.

Based on this, we propose clinical questions: Synovial immunopathological classification helps to achieve accurate diagnosis of RA. Can MTX combined with tofacitinib intensive treatment be applied to newly treated RA patients with synovial myeloid stromal type to achieve early disease control?

This project aims to conduct a randomized, controlled, open label, multicenter clinical study on early intensified treatment of RA based on synovial pathology classification. 130 newly treated adult patients with moderate to severe active rheumatoid arthritis (RA) of the synovial medullary matrix type were randomly divided into an intensive treatment group and a conventional treatment group in a 1:1 ratio. The intensive treatment group was treated with MTX combined with tofacitinib, while the conventional treatment group was treated with MTX monotherapy. The expected intervention period is 12 weeks, with a follow-up period of 48 weeks. The primary endpoint is the proportion of subjects who achieved ACR20 at week 12. Secondary endpoint indicators include improvement in disease activity and joint function among subjects at different follow-up points, safety, and the proportion of subjects who experienced joint destruction progression at week 48. The exploratory objective (sub topic) is to apply proteomics to screen serum biomarkers in patients with synovial myeloid stromal RA and establish a precise diagnostic system.

This project is based on the applicant's long-term research on synovial pathology of RA, proposing the concept of achieving accurate diagnosis of RA based on synovial pathology classification. At the same time, it aims to explore the efficacy of early MTX combined with tofacitinib in patients with synovial medullary stromal RA who have poor conventional treatment efficacy, providing high-level clinical evidence for achieving precise initial treatment of RA treatment guidelines.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients were diagnosed according to the 1987 American College of Rheumatology or 2010 American College of Rheumatology/European League Against Rheumatism criteria
  • Patients had moderate or high disease activity
  • Patients had a synovial and with a myeloid-stromal pathotype
  • Patients with good compliance, willing to participate in this study and sign an form

Exclusion criteria

Exclusion Criteria:

  • Patient received conventional synthetic disease modifying anti-rheumatic drugs treatment in the first 12 weeks of randomization
  • Patient received biologic agents treatment in the first 6 months of randomization
  • Patient received Janus kinase inhibitor treatment before randomization
  • Patient with serious diseases under control (such as diabetes), serious respiratory diseases, serious chronic gastrointestinal diseases (such as active or recurrent gastrointestinal ulcers), serious blood system diseases (such as aplastic anemia, myelodysplastic syndrome) or any disease that can cause hemolysis or erythrocyte instability (such as malaria, hemolytic anemia)
  • Patients with moderate to severe congestive heart failure ( grade III or IV), or recent (within 6 months prior to screening) cerebrovascular accident, myocardial infarction, coronary stent implantation, or uncontrolled hypertension
  • Patients with blood routine WBC\<4.0 × 109/L, and/or \<90g/L, and/or Plt\<100 × 109/L during the screening period
  • Patients with active chronic liver disease or abnormal liver function, , ALT, GGT, and are more than twice the during the screening period
  • Patients with estimated \<30ml/min during screening period
  • Patients with history of symptomatic herpes zoster infection (within the first 12 weeks of randomization), recurrent or disseminated (even if only once) herpes zoster or disseminated (even if only once) herpes simplex infection
  • Chest X-ray or CT examination indicates active tuberculosis, or latent tuberculosis (T-SPOT or TB-IGRA positive) without prophylactic tuberculosis treatment for at least 4 weeks
  • Patients woth virus ribonucleic acid (HCV-RNA) testing are higher than the lower limit of detection; Or positive for Treponema pallidum antibody (TP Ab); Or antibody (HIV Ab) positive during the selected period
  • Patients with surface antigen positive without prophylactic antiviral treatment
  • Patients with history of lymphoproliferative diseases, or possibly various signs or symptoms of lymphoproliferative diseases
  • Patients with any active malignant tumors or history of malignant tumors within the first 5 years, except for skin squamous or basal cell carcinoma, cervical carcinoma in situ, or breast ductal carcinoma in situ that has been treated and considered cured
  • Patients with history of thromboembolism, including deep vein thrombosis, pulmonary embolism, arterial thrombosis, etc., or high risk factors prone to thromboembolism (such as obesity, smoking, abnormal coagulation function, diabetes, long-term use of estrogen or use of compound hormonal or hormone replacement therapy, long-term braking, etc., which are comprehensively judged by the investigator according to clinical evaluation)
  • Patients with undergone major surgery within the first 4 weeks of randomization, or is expected to undergo major surgery after enrollment; Or a history of chronic pain that may affect the evaluation of the study; Or have received organ transplantation before
  • Patients with history of mental illness, alcoholism, drug or other substance abuse
  • Pregnant women, lactating women, and men or women who plan to conceive in the near future
  • The researchers believe that there are any other factors that may affect the progress or evaluation of the results of this study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Methotrexate Combined With Tofacitinib

    Methotrexate 10-15mg orally once a week, tofacitinib 5mg orally twice a day

    Drug: Methotrexate Combined With Tofacitinib

  • Active comparator
    Methotrexate

    Methotrexate 10-15mg orally once a week

    Drug: Methotrexate

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of subjects who achieved ACR20

    ACR20

    Time frame: 12 week

Secondary outcomes

  1. Changes in disease activity scores (DAS28-CRP) relative to baseline

    DAS28-CRP

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

  2. Changes in disease activity scores (DAS28-ESR) relative to baseline

    DAS28-ESR

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

  3. Changes in disease activity scores (SDAI) relative to baseline

    SDAI

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

  4. Changes in disease activity scores (CDAI) relative to baseline

    CDAI

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

  5. Proportion of subjects with low disease activity and remission (SDAI standard) at weeks 4, 8, 12, 24, 36, and 48 after treatment

    low disease activity and remission

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

  6. The proportion of subjects who met ACR50 criteria at weeks 4, 8, 12, 24, 36, and 48 after treatment

    ACR50

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

  7. The proportion of subjects who met ACR70 criteria at weeks 4, 8, 12, 24, 36, and 48 after treatment

    ACR70

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

  8. Changes in the Disability Index (HAQ-DI) of the Health Assessment Questionnaire relative to baseline

    HAQ-DI

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

  9. Changes in EQ-5D-5L relative to baseline

    EQ-5D-5L

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

  10. The proportion of subjects with joint destruction progression at 48 weeks after treatment

    joint destruction progression

    Time frame: 48 weeks

Other outcomes

  1. The proportion of adverse events (AE) in subjects at 4, 8, 12, 24, 36, and 48 weeks after treatment

    adverse events (AE)

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

  2. The proportion of severe adverse events (SAE) in subjects at 4, 8, 12, 24, 36, and 48 weeks after treatment

    severe adverse events (SAE)

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

  3. Changes in serum MMP-3 levels relative to baseline

    serum MMP-3 levels

    Time frame: 4, 8, 12, 24, 36, and 48 weeks after treatment

07

Study locations

5 of 5 sites recruiting
  • Foshan Hopsital of Traditional Chinese Medicine
    Foshan, Guangdong 528000, China
    Recruiting
  • Sun Yat-sen Memorial Hospital
    Guangzhou, Guangdong 510120, China
    Recruiting
  • The Affiliated Panyu Central Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 511400, China
    Recruiting
  • Pu Ning Shi Ren Ming Yi Yuan
    Jieyang, Guangdong 515300, China
    Recruiting
  • Shenshan Medical Central, Memorial Hospital of Sun Yat-sen University
    Shantou, Guangdong 516621, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2029, 63 months after the start.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 63 months is above that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Mar 8, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06301373
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Sep 1, 2024
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 12, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Tofacitinib

Start the discussion